AR063448A1 - Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) - Google Patents
Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)Info
- Publication number
- AR063448A1 AR063448A1 ARP070104873A ARP070104873A AR063448A1 AR 063448 A1 AR063448 A1 AR 063448A1 AR P070104873 A ARP070104873 A AR P070104873A AR P070104873 A ARP070104873 A AR P070104873A AR 063448 A1 AR063448 A1 AR 063448A1
- Authority
- AR
- Argentina
- Prior art keywords
- vegf
- human
- molecules
- growth factor
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Radiology & Medical Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Moléculas polipeptídicas recombinantes relacionadas con anticuerpos, que reconocen específicamente el Factor de Crecimiento de Endotelio Vascular-A (VEGF-A) humano, e interfieren con sus efectos estimulatorios in vitro, y pro-angiogénicos in vivo. Dichas moléculas polipeptídicas recombinantes son capaces de afectar la proliferacion de células endoteliales humanas in vitro, la angiogénesis subcutánea en ratones inducida por tapones de Matrigel que contienen VEGF-A, y el crecimiento de tumores humanos transplantados a ratones desnudos. Varias de estas moléculas previenen la neovascularizacion coroidea en un modelo experimental en primates no humanos. Estas moléculas pueden emplearse para la inmunoterapia pasiva de entidades patologicas cuyo curso se asocia al aumento de la vasculatura, tales como la degeneracion macular asociada a la edad (variante humeda), el cáncer y sus metástasis, los glaucomas neovasculares, la retinopatía diabética y del recién nacido, los procesos inflamatorios agudos y cronicos, enfermedades infecciosas, enfermedades autoinmunes, el rechazo al transplante de organos, los hemangiomas y los angiofibromas, entre otros. Reivindicacion 1: Anticuerpos recombinantes caracterizados porque comprenden regiones variables de inmunoglobulinas humanas codificadas por las secuencias nucleotídicas SEC ID N°: 7 y SEQ ID N°: 8, o secuencias homologas, que reconocen un epítope en el VEGF-A humano definido alrededor de, aunque no necesariamente limitado a, sus residuos C102, C57, R56, T31 y L32, e interfieren con su efecto pro-angiogénico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20060208A CU23636A1 (es) | 2006-11-01 | 2006-11-01 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063448A1 true AR063448A1 (es) | 2009-01-28 |
Family
ID=39148565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104873A AR063448A1 (es) | 2006-11-01 | 2007-11-01 | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100151566A1 (es) |
| EP (1) | EP2093236A1 (es) |
| JP (1) | JP2010508033A (es) |
| KR (1) | KR20090078363A (es) |
| CN (1) | CN101573379A (es) |
| AR (1) | AR063448A1 (es) |
| AU (1) | AU2007315484A1 (es) |
| BR (1) | BRPI0717971A2 (es) |
| CA (1) | CA2667594A1 (es) |
| CO (1) | CO6341480A2 (es) |
| CU (1) | CU23636A1 (es) |
| MX (1) | MX2009004765A (es) |
| RU (1) | RU2009120536A (es) |
| WO (1) | WO2008052489A1 (es) |
| ZA (1) | ZA200903017B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101093717B1 (ko) * | 2008-11-26 | 2011-12-19 | 한국생명공학연구원 | Ｖｅｇｆ―특이적인 인간항체 |
| CU23895B1 (es) * | 2010-12-28 | 2013-05-31 | Biorec Sa | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) obtenidos mediante mutagénesis de regiones variables |
| CN103012588A (zh) * | 2011-09-23 | 2013-04-03 | 武汉吉天朋生物科技发展有限公司 | 利用具有中和VEGFA生物学活性的McAb应用于肿瘤的靶向治疗 |
| CN104073502B (zh) * | 2013-03-26 | 2016-08-24 | 华东师范大学 | 人脑钠肽的中和性基因工程抗体3c1及其制备方法和应用 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| CL2014002941A1 (es) * | 2014-10-30 | 2015-04-06 | Univ Concepcion | Moléculas polipeptídicas contra el factor de crecimiento del endotelio vascular (vegf) |
| IL290457B1 (en) | 2015-12-30 | 2024-10-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CU20210101A7 (es) | 2021-12-15 | 2023-07-12 | Ct Ingenieria Genetica Biotecnologia | Polipéptidos que se unen a factores de crecimiento proangiogénicos |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0438200B1 (en) | 1990-01-16 | 2002-07-17 | Centro De Ingenieria Genetica Y Biotecnologia | Method for the expression of heterologous genes in the yeast Pichia pastoris, expression vectors and transformed microorganisms |
| WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2006
- 2006-11-01 CU CU20060208A patent/CU23636A1/es unknown
-
2007
- 2007-10-30 BR BRPI0717971-5A2A patent/BRPI0717971A2/pt not_active IP Right Cessation
- 2007-10-30 CN CNA2007800437331A patent/CN101573379A/zh active Pending
- 2007-10-30 JP JP2009534978A patent/JP2010508033A/ja not_active Abandoned
- 2007-10-30 RU RU2009120536/10A patent/RU2009120536A/ru not_active Application Discontinuation
- 2007-10-30 US US12/447,711 patent/US20100151566A1/en not_active Abandoned
- 2007-10-30 MX MX2009004765A patent/MX2009004765A/es unknown
- 2007-10-30 KR KR1020097011229A patent/KR20090078363A/ko not_active Application Discontinuation
- 2007-10-30 AU AU2007315484A patent/AU2007315484A1/en not_active Abandoned
- 2007-10-30 WO PCT/CU2007/000019 patent/WO2008052489A1/es active Search and Examination
- 2007-10-30 CA CA002667594A patent/CA2667594A1/en not_active Abandoned
- 2007-10-30 EP EP07817383A patent/EP2093236A1/en not_active Withdrawn
- 2007-11-01 AR ARP070104873A patent/AR063448A1/es not_active Application Discontinuation
-
2009
- 2009-04-30 ZA ZA200903017A patent/ZA200903017B/xx unknown
- 2009-06-01 CO CO09056360A patent/CO6341480A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2667594A1 (en) | 2008-05-08 |
| EP2093236A1 (en) | 2009-08-26 |
| CU23636A1 (es) | 2011-03-21 |
| RU2009120536A (ru) | 2010-12-10 |
| ZA200903017B (en) | 2010-03-31 |
| WO2008052489A8 (es) | 2009-07-23 |
| CO6341480A2 (es) | 2011-11-21 |
| US20100151566A1 (en) | 2010-06-17 |
| AU2007315484A1 (en) | 2008-05-08 |
| MX2009004765A (es) | 2009-06-05 |
| CN101573379A (zh) | 2009-11-04 |
| BRPI0717971A2 (pt) | 2013-11-12 |
| KR20090078363A (ko) | 2009-07-17 |
| JP2010508033A (ja) | 2010-03-18 |
| WO2008052489A1 (es) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063448A1 (es) | Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf) | |
| Farhadihosseinabadi et al. | Amniotic membrane and its epithelial and mesenchymal stem cells as an appropriate source for skin tissue engineering and regenerative medicine | |
| Libro et al. | The role of the Wnt canonical signaling in neurodegenerative diseases | |
| ECSP099379A (es) | Anticuerpos anti-factor d humanizados | |
| Xue et al. | Effects of human bone marrow mesenchymal stem cells on burn injury healing in a mouse model | |
| RU2017111300A (ru) | Центральные т-клетки памяти для адоптивной т-клеточной терапии | |
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| CR11817A (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| CU23178A1 (es) | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA | |
| PE20141149A1 (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| WO2011139357A8 (en) | Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases | |
| CR20140047A (es) | Dominios variables singulares anti-vgf fusionados con dominios de fc | |
| King et al. | CD1d-invariant natural killer T cell-based cancer immunotherapy: α-galactosylceramide and beyond | |
| UY33047A (es) | Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes | |
| PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| PE20190907A1 (es) | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas | |
| Barzelay et al. | Adipose‐Derived Mesenchymal Stem Cells Migrate and Rescue RPE in the Setting of Oxidative Stress | |
| EA201391154A3 (ru) | Способы и композиции для нацеливания на адипоциты у млекопитающих | |
| CL2021003081A1 (es) | Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813) | |
| Tahiri et al. | P75 neurotrophin receptor participates in the choroidal antiangiogenic and apoptotic effects of T-lymphocyte–derived microparticles | |
| Van Pham et al. | Production of endothelial progenitor cells from skin fibroblasts by direct reprogramming for clinical usages | |
| Ojeda et al. | Expression of CXCL12 and CXCL14 during eye development in chick and mouse | |
| Yan et al. | Limbal stem cells and corneal epithelial regeneration: current status and prospectives | |
| Abud et al. | The effect of transient local anti-inflammatory treatment on the survival of pig retinal progenitor cell allotransplants | |
| MX2020003550A (es) | Anticuerpos monoclonales anti-trkb y metodos de uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |